The VIVI Cap 1 shields insulin in-use from potential temperature damage. Thus, reducing the risk of using damaged insulin and wasting money from discarded insulin that might have been compromised.
Project RE will focus on finding therapies to tackle viral entry and replication and is co-led between Mila (Quebec AI Institute) and Relation Therapeutics, with the overall scientific direction by Mila founder Professor Yoshua Bengio.
